京西國際(02339.HK)預計中期由盈轉虧逾4400萬港元
格隆匯8月19日丨京西國際(02339.HK)公告,公司預計截至2020年6月30日止6個月錄得綜合淨虧損不少於約4400萬港元,上年同期淨利潤約2356萬港元。這種不利變化主要是由於在全球出現新型冠狀病毒(COVID-19)疫情之後,歐洲多國在2020年第二季度實施了遏制及緩和措施,這導致集團在英國、波蘭和捷克共和國的廠房中斷及暫停營運。
此外,集團的主要客户是歐洲知名汽車製造商。彼等亦受到大流行病的負面影響。由於上述因素,期間集團的收益受到重大不利影響。從2020年6月開始,集團在廠房實施了新的安全措施,並以分階段形式恢復生產營運。於2020年6月30日,集團所有廠房已恢復生產營運。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.